91 related articles for article (PubMed ID: 31900282)
1. Investigating New Mechanisms of Acquired Resistance to Targeted Therapies: If You Hit Them Harder, Do They Get Up Differently?
Floros KV; Hata AN; Faber AC
Cancer Res; 2020 Jan; 80(1):25-26. PubMed ID: 31900282
[TBL] [Abstract][Full Text] [Related]
2. Overexpression of PI3K p110α contributes to acquired resistance to MET inhibitor, in MET-amplified SNU-5 gastric xenografts.
Ji F; Liu X; Wu Y; Fang X; Huang G
Drug Des Devel Ther; 2015; 9():5697-704. PubMed ID: 26543351
[TBL] [Abstract][Full Text] [Related]
3. Regulation of MET kinase inhibitor resistance by copy number of MET in gastric carcinoma cells.
Funakoshi Y; Mukohara T; Ekyalongo RC; Tomioka H; Kataoka Y; Shimono Y; Chayahara N; Toyoda M; Kiyota N; Fujiwara Y; Minami H
Oncol Res; 2013; 21(6):287-93. PubMed ID: 25198658
[TBL] [Abstract][Full Text] [Related]
4. Prolonged MEK inhibition leads to acquired resistance and increased invasiveness in KRAS mutant gastric cancer.
Choi KM; Cho E; Kim E; Shin JH; Kang M; Kim B; Han EH; Chung YH; Kim JY
Biochem Biophys Res Commun; 2018 Dec; 507(1-4):311-318. PubMed ID: 30466782
[TBL] [Abstract][Full Text] [Related]
5. A Single-Step, High-Dose Selection Scheme Reveals Distinct Mechanisms of Acquired Resistance to Oncogenic Kinase Inhibition in Cancer Cells.
Finn KJ; Martin SE; Settleman J
Cancer Res; 2020 Jan; 80(1):79-90. PubMed ID: 31641034
[TBL] [Abstract][Full Text] [Related]
6. Dynamic reprogramming of signaling upon met inhibition reveals a mechanism of drug resistance in gastric cancer.
Lai AZ; Cory S; Zhao H; Gigoux M; Monast A; Guiot MC; Huang S; Tofigh A; Thompson C; Naujokas M; Marcus VA; Bertos N; Sehat B; Perera RM; Bell ES; Page BD; Gunning PT; Ferri LE; Hallett M; Park M
Sci Signal; 2014 Apr; 7(322):ra38. PubMed ID: 24757178
[TBL] [Abstract][Full Text] [Related]
7. Testican-1-mediated epithelial-mesenchymal transition signaling confers acquired resistance to lapatinib in HER2-positive gastric cancer.
Kim HP; Han SW; Song SH; Jeong EG; Lee MY; Hwang D; Im SA; Bang YJ; Kim TY
Oncogene; 2014 Jun; 33(25):3334-41. PubMed ID: 23873022
[TBL] [Abstract][Full Text] [Related]
8. [MET receptor inhibition: Hope against resistance to targeted therapies?].
Hochart A; Leblond P; Le Bourhis X; Meignan S; Tulasne D
Bull Cancer; 2017 Feb; 104(2):157-166. PubMed ID: 27863726
[TBL] [Abstract][Full Text] [Related]
9. MET and KRAS gene amplification mediates acquired resistance to MET tyrosine kinase inhibitors.
Cepero V; Sierra JR; Corso S; Ghiso E; Casorzo L; Perera T; Comoglio PM; Giordano S
Cancer Res; 2010 Oct; 70(19):7580-90. PubMed ID: 20841479
[TBL] [Abstract][Full Text] [Related]
10. Circulating tumor DNA profiling by next generation sequencing reveals heterogeneity of crizotinib resistance mechanisms in a gastric cancer patient with MET amplification.
Du J; Wu X; Tong X; Wang X; Wei J; Yang Y; Chang Z; Mao Y; Shao YW; Liu B
Oncotarget; 2017 Apr; 8(16):26281-26287. PubMed ID: 28460431
[TBL] [Abstract][Full Text] [Related]
11. MET Gene Amplification and MET Receptor Activation Are Not Sufficient to Predict Efficacy of Combined MET and EGFR Inhibitors in EGFR TKI-Resistant NSCLC Cells.
Presutti D; Santini S; Cardinali B; Papoff G; Lalli C; Samperna S; Fustaino V; Giannini G; Ruberti G
PLoS One; 2015; 10(11):e0143333. PubMed ID: 26580964
[TBL] [Abstract][Full Text] [Related]
12. Acquired Resistance to Crizotinib in NSCLC with MET Exon 14 Skipping.
Heist RS; Sequist LV; Borger D; Gainor JF; Arellano RS; Le LP; Dias-Santagata D; Clark JW; Engelman JA; Shaw AT; Iafrate AJ
J Thorac Oncol; 2016 Aug; 11(8):1242-1245. PubMed ID: 27343442
[TBL] [Abstract][Full Text] [Related]
13. Identification of short-form RON as a novel intrinsic resistance mechanism for anti-MET therapy in MET-positive gastric cancer.
Wu Z; Zhang Z; Ge X; Lin Y; Dai C; Chang J; Liu X; Geng R; Wang C; Chen H; Sun M; Guo W; Li J
Oncotarget; 2015 Dec; 6(38):40519-34. PubMed ID: 26528757
[TBL] [Abstract][Full Text] [Related]
14. Amplification of MET may identify a subset of cancers with extreme sensitivity to the selective tyrosine kinase inhibitor PHA-665752.
Smolen GA; Sordella R; Muir B; Mohapatra G; Barmettler A; Archibald H; Kim WJ; Okimoto RA; Bell DW; Sgroi DC; Christensen JG; Settleman J; Haber DA
Proc Natl Acad Sci U S A; 2006 Feb; 103(7):2316-21. PubMed ID: 16461907
[TBL] [Abstract][Full Text] [Related]
15. Depletion of FOXM1 via MET Targeting Underlies Establishment of a DNA Damage-Induced Senescence Program in Gastric Cancer.
Francica P; Nisa L; Aebersold DM; Langer R; Bladt F; Blaukat A; Stroka D; Martínez MR; Zimmer Y; Medová M
Clin Cancer Res; 2016 Nov; 22(21):5322-5336. PubMed ID: 27185371
[TBL] [Abstract][Full Text] [Related]
16. Targeting the MET Pathway in Gastric and Oesophageal Cancers: Refining the Optimal Approach.
Lee J; Tran P; Klempner SJ
Clin Oncol (R Coll Radiol); 2016 Aug; 28(8):e35-44. PubMed ID: 26880063
[TBL] [Abstract][Full Text] [Related]
17. Current mechanism of acquired resistance to epidermal growth factor receptor-tyrosine kinase inhibitors and updated therapy strategies in human nonsmall cell lung cancer.
Zhang K; Yuan Q
J Cancer Res Ther; 2016 Dec; 12(Supplement):C131-C137. PubMed ID: 28230005
[TBL] [Abstract][Full Text] [Related]
18. FOXO1 Suppression is a Determinant of Acquired Lapatinib-Resistance in HER2-Positive Gastric Cancer Cells Through MET Upregulation.
Park J; Choi Y; Ko YS; Kim Y; Pyo JS; Jang BG; Kim MA; Lee JS; Chang MS; Park JW; Lee BL
Cancer Res Treat; 2018 Jan; 50(1):239-254. PubMed ID: 28343375
[TBL] [Abstract][Full Text] [Related]
19. Crizotinib-resistant
Shen B; Wu F; Ye J; Liang R; Wang R; Yu R; Wu X; Shao YW; Feng J
Future Oncol; 2019 Aug; 15(22):2585-2593. PubMed ID: 31339066
[No Abstract] [Full Text] [Related]
20. Truncated RAF kinases drive resistance to MET inhibition in MET-addicted cancer cells.
Petti C; Picco G; Martelli ML; Trisolini E; Bucci E; Perera T; Isella C; Medico E
Oncotarget; 2015 Jan; 6(1):221-33. PubMed ID: 25473895
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
